Quantification of DNA methylation for carcinogenic risk estimation in patients with non-alcoholic steatohepatitis

Clinical Epigenetics

Table 4 Discrimination of non-cancerous liver tissue showing non-alcoholic steatohepatitis (NASH) from patients with hepatocellular carcinoma (NASH-W) from normal liver tissue (NLT) based on the relative DNA methylation rates determined by anion-exchange high-performance liquid chromatography analysis in the initial and validation cohorts

PCR product ID^a	Probe ID^a	Initial cohort (n = 50)				Validation cohort (n = 33)
PCR product ID^a	Probe ID^a	Area under the curve	Cutoff value^b	Sensitivity^c	Specificity^d	Sensitivity^c	Specificity^d
1	cg09580822	0.965	0.667	0.853	0.933	0.909	0.364
2	cg15050398	0.980	1.000	0.900	0.933	0.909	0.227
3	cg18210511	0.865	0.641	0.900	0.759	1.000	0.864
4	cg09580859	0.812	0.849	0.900	0.770	1.000	0.818
5	cg13719443	0.850	0.408	0.900	0.730	0.811	0.727

^aPCR product ID encompassing five marker CpG (Infinium HumanMethylation450 BeadChip probe) sites is shown in Additional file 1: Table S2
^bYouden index based on the receiver operating characteristic curve was used as the cutoff value for the discrimination
^cSensitivity was defined as the ratio of the number of tissue samples predicted to be NASH-W and/or carcinogenic risk-positive based on the criteria relative to the exact number of NASH-W samples
^dSpecificity was defined as the ratio of the number of tissue samples not predicted to be NASH-W and/or predicted to be carcinogenic risk-negative based on the criteria relative to the exact number of NLT samples. Markers for which sufficient sensitivity and specificity were validated in the validation cohort are underlined

ISSN: 1868-7083